Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL
2022
Preuzimanje 🢃
Autori
Vekić, JelenaZeljković, Aleksandra
Stefanović, Aleksandra
Bogavac-Stanojević, Nataša
Ilias, Ioannis
Silva-Nunes, José
Pantea Stoian, Anca
Janez, Andrej
Rizzo, Manfredi
Članak u časopisu (Objavljena verzija)
Metapodaci
Prikaz svih podataka o dokumentuApstrakt
Compelling evidence supports the causative link between increased levels of low-density lipoprotein cholesterol (LDL-C) and atherosclerotic cardiovascular disease (CVD) development. For that reason, the principal aim of primary and secondary cardiovascular prevention is to reach and sustain recommended LDL-C goals. Although there is a considerable body of evidence that shows that lowering LDL-C levels is directly associated with CVD risk reduction, recent data shows that the majority of patients across Europe cannot achieve their LDL-C targets. In attempting to address this matter, a new overarching concept of a lipid-lowering approach, comprising of even more intensive, much earlier and longer intervention to reduce LDL-C level, was recently proposed for high-risk patients. Another important concern is the residual risk for recurrent cardiovascular events despite optimal LDL-C reduction, suggesting that novel lipid biomarkers should also be considered as potential therapeutic targets.... Among them, small dense LDL particles (sdLDL) seem to have the most significant potential for therapeutic modulation. This paper discusses the potential of traditional and emerging lipid-lowering approaches for cardiovascular prevention by targeting sdLDL particles.
Ključne reči:
cholesterol / lipids / lipoproteins / prevention / small dense LDL / therapyIzvor:
Pharmaceutics, 2022, 14, 4Izdavač:
- MDPI
Finansiranje / projekti:
- Ministarstvo nauke, tehnološkog razvoja i inovacija Republike Srbije, institucionalno finansiranje - 200161 (Univerzitet u Beogradu, Farmaceutski fakultet) (RS-MESTD-inst-2020-200161)
DOI: 10.3390/pharmaceutics14040825
ISSN: 1999-4923
WoS: 000786006100001
Scopus: 2-s2.0-85129120336
Institucija/grupa
PharmacyTY - JOUR AU - Vekić, Jelena AU - Zeljković, Aleksandra AU - Stefanović, Aleksandra AU - Bogavac-Stanojević, Nataša AU - Ilias, Ioannis AU - Silva-Nunes, José AU - Pantea Stoian, Anca AU - Janez, Andrej AU - Rizzo, Manfredi PY - 2022 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4100 AB - Compelling evidence supports the causative link between increased levels of low-density lipoprotein cholesterol (LDL-C) and atherosclerotic cardiovascular disease (CVD) development. For that reason, the principal aim of primary and secondary cardiovascular prevention is to reach and sustain recommended LDL-C goals. Although there is a considerable body of evidence that shows that lowering LDL-C levels is directly associated with CVD risk reduction, recent data shows that the majority of patients across Europe cannot achieve their LDL-C targets. In attempting to address this matter, a new overarching concept of a lipid-lowering approach, comprising of even more intensive, much earlier and longer intervention to reduce LDL-C level, was recently proposed for high-risk patients. Another important concern is the residual risk for recurrent cardiovascular events despite optimal LDL-C reduction, suggesting that novel lipid biomarkers should also be considered as potential therapeutic targets. Among them, small dense LDL particles (sdLDL) seem to have the most significant potential for therapeutic modulation. This paper discusses the potential of traditional and emerging lipid-lowering approaches for cardiovascular prevention by targeting sdLDL particles. PB - MDPI T2 - Pharmaceutics T1 - Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL VL - 14 IS - 4 DO - 10.3390/pharmaceutics14040825 ER -
@article{ author = "Vekić, Jelena and Zeljković, Aleksandra and Stefanović, Aleksandra and Bogavac-Stanojević, Nataša and Ilias, Ioannis and Silva-Nunes, José and Pantea Stoian, Anca and Janez, Andrej and Rizzo, Manfredi", year = "2022", abstract = "Compelling evidence supports the causative link between increased levels of low-density lipoprotein cholesterol (LDL-C) and atherosclerotic cardiovascular disease (CVD) development. For that reason, the principal aim of primary and secondary cardiovascular prevention is to reach and sustain recommended LDL-C goals. Although there is a considerable body of evidence that shows that lowering LDL-C levels is directly associated with CVD risk reduction, recent data shows that the majority of patients across Europe cannot achieve their LDL-C targets. In attempting to address this matter, a new overarching concept of a lipid-lowering approach, comprising of even more intensive, much earlier and longer intervention to reduce LDL-C level, was recently proposed for high-risk patients. Another important concern is the residual risk for recurrent cardiovascular events despite optimal LDL-C reduction, suggesting that novel lipid biomarkers should also be considered as potential therapeutic targets. Among them, small dense LDL particles (sdLDL) seem to have the most significant potential for therapeutic modulation. This paper discusses the potential of traditional and emerging lipid-lowering approaches for cardiovascular prevention by targeting sdLDL particles.", publisher = "MDPI", journal = "Pharmaceutics", title = "Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL", volume = "14", number = "4", doi = "10.3390/pharmaceutics14040825" }
Vekić, J., Zeljković, A., Stefanović, A., Bogavac-Stanojević, N., Ilias, I., Silva-Nunes, J., Pantea Stoian, A., Janez, A.,& Rizzo, M.. (2022). Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL. in Pharmaceutics MDPI., 14(4). https://doi.org/10.3390/pharmaceutics14040825
Vekić J, Zeljković A, Stefanović A, Bogavac-Stanojević N, Ilias I, Silva-Nunes J, Pantea Stoian A, Janez A, Rizzo M. Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL. in Pharmaceutics. 2022;14(4). doi:10.3390/pharmaceutics14040825 .
Vekić, Jelena, Zeljković, Aleksandra, Stefanović, Aleksandra, Bogavac-Stanojević, Nataša, Ilias, Ioannis, Silva-Nunes, José, Pantea Stoian, Anca, Janez, Andrej, Rizzo, Manfredi, "Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL" in Pharmaceutics, 14, no. 4 (2022), https://doi.org/10.3390/pharmaceutics14040825 . .